Literature DB >> 29851153

Burden of non-alcoholic fatty liver disease in Australia.

Suzanne E Mahady1,2, Leon A Adams3,4.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease in the Australian population, although precise estimates of prevalence are lacking. NAFLD may progress to liver fibrosis, cirrhosis, decompensated liver disease, and liver cancer and is becoming an increasingly common indication for liver transplantation in Australia and New Zealand. There is an extrahepatic burden of NAFLD extending beyond the liver, which is manifested by an increased risk of developing cardiovascular disease, diabetes, and chronic renal impairment, all of which are common causes of morbidity in the Australian population. Early recognition of those patients at high risk of developing advanced liver disease is essential in order to target those who will benefit from intensive lifestyle modification. In this review, we present data on the epidemiology of NAFLD within Australia, its associated health burden in terms of hepatic and extrahepatic complications, common clinical presentations, and indications for treatment. We also propose a research agenda that highlights knowledge needed to improve diagnosis and management specific to the Australian context.
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  cirrhosis; fatty liver; general population; prevalence

Mesh:

Year:  2018        PMID: 29851153     DOI: 10.1111/jgh.14270

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

Review 1.  Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology.

Authors:  Davide Gnocchi; Carlo Custodero; Carlo Sabbà; Antonio Mazzocca
Journal:  J Mol Med (Berl)       Date:  2019-04-05       Impact factor: 4.599

2.  The Association Between Chronic Plaque Psoriasis and Nonalcoholic Fatty Liver Disease in Indian Patients: Results of a Pilot Study.

Authors:  Vikram K Mahajan; Narvir S Chauhan; Baldev S Rana; Karaninder S Mehta; Sheenam Hooda; Pushpinder S Chauhan; Amisha Kukreja
Journal:  J Clin Exp Hepatol       Date:  2021-12-03

Review 3.  General Overview About the Current Management of Nonalcoholic Fatty Liver Disease.

Authors:  Javier Ampuero
Journal:  Clin Drug Investig       Date:  2022-04-25       Impact factor: 3.580

4.  Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD).

Authors:  David Brain; James O'Beirne; Ingrid J Hickman; Elizabeth E Powell; Patricia C Valery; Sanjeewa Kularatna; Ruth Tulleners; Alison Farrington; Leigh Horsfall; Adrian Barnett
Journal:  BMC Health Serv Res       Date:  2020-04-21       Impact factor: 2.655

5.  Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.

Authors:  Lorraine McSweeney; Matthew Breckons; Gulnar Fattakhova; Yemi Oluboyede; Luke Vale; Laura Ternent; Maria-Magdalena Balp; Lynda Doward; Clifford A Brass; Fiona Beyer; Arun Sanyal; Quentin M Anstee
Journal:  JHEP Rep       Date:  2020-03-06

6.  Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM.

Authors:  Patricia C Valery; Elizabeth E Powell; Kelly Lee Hayward; Amy L Johnson; Leigh U Horsfall; Chris Moser
Journal:  BMJ Open Gastroenterol       Date:  2021-02

7.  The Role of Gut Microbiota in Duodenal-Jejunal Bypass Surgery-Induced Improvement of Hepatic Steatosis in HFD-Fed Rats.

Authors:  Yi Gao; Jia Zhang; Xiao Xiao; Yifan Ren; Xiaopeng Yan; Jing Yue; Tieyan Wang; Zheng Wu; Yi Lv; Rongqian Wu
Journal:  Front Cell Infect Microbiol       Date:  2021-04-02       Impact factor: 5.293

8.  Serum Glycoprotein Markers in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Prasanna Ramachandran; Gege Xu; Hector H Huang; Rachel Rice; Bo Zhou; Klaus Lindpaintner; Daniel Serie
Journal:  J Proteome Res       Date:  2022-03-14       Impact factor: 4.466

9.  Screening for non-alcoholic fatty liver disease in community setting: A cohort study using controlled attenuation parameter-transient elastography.

Authors:  Nicha Teeratorn; Panida Piyachaturawat; Kessarin Thanapirom; Roongruedee Chaiteerakij; Kanokwan Sonsiri; Piyawat Komolmit; Pisit Tangkijvanich; Rungsun Rerknimitr; Leon Adams; Sombat Treeprasertsuk
Journal:  JGH Open       Date:  2019-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.